Cytoxan

Phase 3Small molecule

UUS Oncology Research

Cytoxan is one of 96 small molecule programs targeting Neuroblastoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaActive, not recruiting

Breast CancerCompleted

High-Risk NeuroblastomaRecruiting

Pediatric Solid TumorsActive, not recruiting

Stem Cell TransplantationRecruiting

NeuroblastomaPhase 2

Active, not recruiting

Breast CancerPhase 3

Completed

High-Risk NeuroblastomaPhase 2

Recruiting

Pediatric Solid TumorsPhase 1

Active, not recruiting

Stem Cell TransplantationPhase 2

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cytoxan

UUS Oncology Research

Phase 3

4 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Nubain

AAultman Health Foundation

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 8

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Breast Cancer

NCT06409390

N/ARecruiting

Induction Therapy

NCT05936086

PreclinicalActive, not recruiting

Neuroblastoma

NCT01192555

Q3 2027

Phase 1/2Recruiting

Stem Cell Transplantation

NCT04224558

Q3 2029

Phase 2Recruiting

High-Risk Neuroblastoma

NCT06528496

Q4 2030

Phase 1Active, not recruiting

Neuroblastoma

NCT01822652

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Completed·—·Phase 2·NCT00136539·41 enrolled

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06409390·15 enrolled

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038402·74 enrolled

Show 1 more trial

Adj TC + Herceptin Early Stage Breast Cancer

Completed·UUS Oncology Research·Phase 2·NCT00493649·493 enrolled

Hematologic Malignancies3 trials

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01203722·87 enrolled

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264039·30 enrolled

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264078·30 enrolled

Multiple Myeloma2 trials

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT05008536·27 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

Acute Myeloid Leukemia2 trials

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT05016063·32 enrolled

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT05008575·27 enrolled

Hematological Malignancies2 trials

Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies

Withdrawn·—·N/A·NCT01247688

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Completed·AAlla Keyzner·Phase 1·NCT03885947·7 enrolled

19 more indications

Neuroblastoma2 trials

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Active, not recruiting·—·Phase 1·NCT01822652·11 enrolled

A Phase I/II Study Using Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)

Active, not recruiting·BBaylor College of Medicine·Preclinical·NCT01192555·11 enrolled

Liver Cancer2 trials

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Withdrawn·—·Phase 1·NCT04093648

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

Recruiting·BBaylor College of Medicine·Phase 1·NCT04715191·24 enrolled

Pediatric Disorder1 trial

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Completed·—·N/A·NCT00950846·40 enrolled

Solid Cancer1 trial

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Active, not recruiting·RRampart Health, L.L.C.·Phase 2·NCT04713371·32 enrolled

Adenocarcinoma1 trial

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Completed·RRampart Health, L.L.C.·Phase 2·NCT04090775·12 enrolled

Transplantation1 trial

DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse

Completed·UUniversity of Arkansas·Phase 2·NCT00083681·180 enrolled

Induction Therapy1 trial

A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH

Recruiting·Sshifeng Lou·N/A·NCT05936086·160 enrolled

Recurrence1 trial

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Completed·EEmory University·Phase 2·NCT00941330·31 enrolled

Chronic Lymphocytic Leukemia1 trial

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·SSteven E. Coutre·Phase 2·NCT00230282·25 enrolled

Bone Marrow Transplantation1 trial

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02995330·3 enrolled

Ewing's Sarcoma1 trial

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Safety and Efficacy1 trial

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00496873·100 enrolled

Severe Aplastic Anemia1 trial

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Terminated·—·Phase 2·NCT00578903·22 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Lymphoma1 trial

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

Hepatocellular Carcinoma1 trial

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

Completed·—·Phase 1·NCT02905188·9 enrolled

Pediatric Solid Tumors1 trial

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Active, not recruiting·—·Phase 1·NCT02932956·10 enrolled

Human Papillomavirus-Related Carcinoma1 trial

HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers

Completed·BBaylor College of Medicine·Phase 1·NCT02379520·35 enrolled

High-Risk Neuroblastoma1 trial

N10: Reduced Therapy for High-Risk Neuroblastoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06528496·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Cytoxan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytoxan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytoxan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Oncology Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUS Oncology Research

Cytoxan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q3 2029

Q4 2030

Trials by Indication[1]

Breast Cancer4 trials

Hematologic Malignancies3 trials

Multiple Myeloma2 trials

Acute Myeloid Leukemia2 trials

Hematological Malignancies2 trials

Neuroblastoma2 trials

Liver Cancer2 trials

Pediatric Disorder1 trial

Solid Cancer1 trial

Adenocarcinoma1 trial

Transplantation1 trial

Induction Therapy1 trial

Recurrence1 trial

Chronic Lymphocytic Leukemia1 trial

Bone Marrow Transplantation1 trial

Ewing's Sarcoma1 trial

Safety and Efficacy1 trial

Severe Aplastic Anemia1 trial

Stem Cell Transplantation1 trial

Lymphoma1 trial

Hepatocellular Carcinoma1 trial

Pediatric Solid Tumors1 trial

Human Papillomavirus-Related Carcinoma1 trial

High-Risk Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News